Department of Medical Microbiology and Parasitology,
College of Veterinary Medicine, University of Georgia, Athens,
Georgia,1 and Department of
Molecular Biology and Biochemistry and Cancer Research
Institute2 and Department of
Physiology and Biophysics,3 University of
California, Irvine, California
Jaagsiekte sheep retrovirus (JSRV) is the causative agent of a
transmissible lung cancer of sheep known as ovine pulmonary carcinoma.
Recently, we have found that the expression of the JSRV envelope (Env)
is sufficient to transform mouse NIH 3T3 cells in classical
transformation assays. To further investigate the mechanisms of JSRV
oncogenesis, we generated a series of envelope chimeras between JSRV
and the JSRV-related endogenous retroviruses of sheep (enJSRVs) and
assessed them in transformation assays. Chimeras containing the
exogenous JSRV SU region and the enJSRV TM region were unable to
transform NIH 3T3 cells. Additional chimeras containing only the
carboxy-terminal portion of TM (a region that we previously identified
as VR3) of the endogenous envelope with SU and the remaining portion of
TM from the exogenous JSRV were also unable to transform NIH 3T3 cells.
The VR3 region includes the putative membrane-spanning region and
cytoplasmic tail of the JSRV TM glycoprotein; this suggested that the
cytoplasmic tail of the JSRV Env mediates transformation, possibly via
a cell signaling mechanism. Mutations Y590 and M593 in the cytoplasmic tail of the JSRV envelope were sufficient to inhibit the transforming abilities of these constructs. Y590 and M593 are part of a Y-X-X-M motif that is recognized by the phosphatidylinositol 3-kinase (PI-3K).
PI-3K initiates a cell signaling pathway that inhibits apoptosis and is
required for a number of mitogens during the G1-to-S-phase
transition of the cell cycle. PI-3K activates Akt by phosphorylation of
threonine 308 and serine 473. We detected by Western blot analysis
phosphorylated Akt in serum-starved MP1 cells (NIH 3T3 cells
transformed by JSRV) but not in the parental NIH 3T3 cells. These data
indicate that the cytoplasmic tail of the JSRV TM is necessary for cell
transformation and suggest a new mechanism of retroviral
transformation. In addition, the ability to dissociate the function of
the JSRV envelope to mediate viral entry from its transforming capacity
has direct relevance for the design of JSRV-based vectors that target
the differentiated epithelial cells of the lungs.
 |
INTRODUCTION |
Jaagsiekte sheep retrovirus (JSRV) is the
etiological agent of a contagious lung cancer of sheep known as ovine
pulmonary carcinoma (OPC) or sheep pulmonary adenomatosis (4, 16,
30, 36). OPC is a naturally occurring disease in most countries of the world and is characterized by the transformation of the differentiated epithelial cells of the lungs, type II pneumocytes and
Clara cells (17, 33). OPC is being extensively studied for
its similarities with a particular type of human lung cancer known as
bronchioloalveolar carcinoma (BAC) (17, 21, 23, 33). The
causes of BAC are unknown. BAC is not strongly associated with
cigarette smoking, and its incidence appears to be increasing in the
United States (1, 5, 6, 51). Thus, the JSRV/OPC model can
offer a foundation for understanding the molecular mechanisms of type
II pneumocytes and Clara cell transformation, especially considering
the role played by retroviruses in the discovery of cellular oncogenes
(46).
Cell transformation by JSRV is offering a new paradigm for retroviral
oncogenesis (45). The JSRV genome does not contain a
cell-derived oncogene, which would suggest that JSRV induces cell
transformation by insertional activation of proto-oncogenes (46). However, the incubation period in experimentally
inoculated lambs can be as short as 2 to 3 weeks (47, 52),
which appears too short for insertional activation to occur. Our recent
study showed that the expression of the envelope (Env) protein of JSRV is able to transform rodent fibroblasts in vitro (27).
Thus, besides mediating viral entry through the interaction with the cellular receptor, the JSRV Env might also function directly as a viral
oncogene. Recently, the cellular receptor for JSRV has been identified
as the hyaluronidase-2 (Hyal-2) (42), a
glycosylphosphatidylinositol-anchored protein whose function is
not completely known (25). Interestingly, Hyal-2 is
contained within a region on human chromosome 3p21.3 that is deleted in
a substantial frequency of lung tumors, which suggests that it might
function as a tumor suppressor gene (26).
In this study we initially mapped the determinants of cell
transformation of the JSRV envelope. We approached this task by generating a series of chimeric constructs between the envelopes of
JSRV21 (an infectious JSRV molecular clone)
(36) and of two JSRV-related endogenous retroviruses of
sheep (enJS56A1 and enJS5F16) (34). The results indicated
that the cytoplasmic tail of the transmembrane (TM) protein of the JSRV
Env is essential for transformation. Further experiments indicated that
a YXXM motif in the cytoplasmic tail is necessary for transformation
and that in JSRV-transformed cells the PI-3K pathway is activated.
These results suggest a new mechanism of retroviral transformation.
 |
MATERIALS AND METHODS |
Plasmids.
A diagram of the plasmids employed in this study
is shown in Fig. 1. Molecular cloning and
mutagenesis were performed by established procedures (2).
Plasmid pCMV3JS21
GP expressing the JSRV21 envelope under the control of the cytomegalovirus (CMV) immediate-early promoter has been described previously (27).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic of the chimeric and some of the mutant JSRV
Env constructs used in this study. The restriction sites that
facilitated the cloning strategy are indicated. All the constructs have
the same promoter, splice donor, and splice acceptor.
|
|
To facilitate cloning procedures described below, we generated
pCMV3JS21
GP2 by removing most of the cellular
3'-flanking sequences present in the pCMV3JS21
GP plasmid.
pEnvEn and pEnvEn2 have the CMV immediate-early promoter, R,
U5, and the splice donor and splice acceptor sites of pCMV3JS21
GP
but express the entire env of the enJSRV clones en56A1 and
en5F16, respectively (34). The other chimeric plasmids
were derived from pCMV3JS21
GP2 and pEnvEn. The chimeras were named
by identifying the envelope region followed by either "x" for the
exogenous pCMV2JS21
GP or "en" for the endogenous plasmid. For
example, pSUxTMen has the surface (SU) region from the exogenous
envelope and the transmembrane (TM) from the endogenous clone, while
pSUenTMx is the opposite chimera. pSUxTMxVR3en has the SU and most of
TM from the exogenous envelope and the VR3 from the endogenous one,
while pSUenTMenVR3x is the reciprocal chimera. pSUxTMxNruIen has SU,
TM, and the first portion of the VR3 from the exogenous envelope and
the last portion of the VR3 from the endogenous envelope. Single
point mutations of the JSRV Env in the pCMV3JS21
GP construct
were performed by site-directed mutagenesis using standard
PCR-based procedures (2). By conventional
nomenclature, pCMV3JS21
GPY590D and pCMV3JS21
GPY590F have a single
point mutation changing the tyrosine at position 590 to aspartic acid
and phenylalanine, respectively.
Transformation assays and development of JSRV-transformed cell
lines.
Transformation assays were performed as previously
described (27). Briefly, NIH 3T3 cells (3 × 105 per 10-cm tissue culture plate) were grown at
37°C and 5% CO2 in Dulbecco's modified
Eagle's medium (DMEM) and 10% calf serum. Cells were transfected with
28 µg of plasmid DNA using the CalPhos mammalian transfection kit
(Clontech) as recommended by the manufacturer. Each plasmid was tested
in at least three independent transformation assays, with two
independent plasmid preparations for each construct. Approximately
12 h after transfection, cells were washed three times with
phosphate-buffered saline (PBS), and fresh medium was added. Cells were
maintained in culture for 4 to 5 weeks, with the medium replaced every
3 days, and monitored microscopically. Foci of transformed cells were
counted 1 month after transfection. Two transformed foci (MP1 and MP2,
from two separate transformation assays) were picked and expanded to
give JSRV-transformed cell lines.
mRNA analysis.
To analyze the pattern and level of
expression of some of the plasmids used in this study, 293T cells
(approximately 106 cells per 10-cm plate) were
transfected with 28 µg of plasmid DNA and the CalPhos mammalian
transfection kit (Clontech) as recommended by the manufacturer.
Forty-eight hours after transfection, total RNA was extracted using the
RNAqueous-Midi kit (Ambion). RNA preparations were treated with
RNase-free DNase (Qiagen). From 6 to 10 µg of total RNA was denatured
with glyoxal-dimethyl sulfoxide, run in a 1% agarose gel in 10 mM
sodium phosphate, and blotted to nylon membranes (Hybond-N Plus;
Amersham) using established methods (2). Membranes were
hybridized with 32P-labeled JSRV env
probes and subjected to autoradiography by exposure to X-ray film
(28).
Entry assays.
Entry mediated by the mutant and chimeric
envelopes was assessed by the ability of the JSRV envelope to
pseudotype murine leukemia virus (MLV)-based vectors
(41). A 293-based cell line expressing MLV Gag and Pol and
an MLV luciferase vector (GP-293-luc; Clontech) was transfected as
described above with various JSRV env expression plasmids.
Supernatants were collected and stored at
70°C. Subsequently,
serial dilutions of the vector supernatants were used to infect NIH 3T3
cells stably expressing the human Hyal-2. These cells were prepared by
infection of NIH 3T3 cells with an MLV-based vector expressing the
human Hyal-2 protein (provided by Dusty Miller), followed by selection
for the drug resistance marker in the vector (M. Palmarini and H. Fan,
unpublished results).
Experiments were performed twice, with duplicate experiments for each
dilution. Cells were lysed after 72 h, and luciferase assays were
performed using the luciferase assay kit as recommended by the
manufacturer (Promega).
Western blot analysis.
For the detection of Akt, cells were
grown at 37°C and 5% CO2 in DMEM and 10% calf
serum until they reached approximately 80% confluence. Cells were then
washed twice with PBS and grown for another 16 h in DMEM lacking
calf serum. Cells were then lysed in lysis buffer containing 0.5%
NP-40, 50 mM HEPES buffer (pH 7.8), 100 mM sodium fluoride, 10 mM
sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, and 1 protease inhibitor cocktail tablet
(Roche) per 50 ml of lysis buffer. From 5 to 10 µg of cell lysate was
subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE)-Western blotting following standard procedures
(2). Filters were incubated with polyclonal rabbit
antiserum to either Akt (cell signaling), Akt phosphorylated in serine
473 (cell signaling), or Akt phosphorylated in threonine 308 (cell
signaling) and detected with a donkey anti-rabbit immunoglobulin
labeled with horseradish peroxidase (Amersham), followed by an enhanced
chemiluminescence detection system (Supersignal; Pierce) as recommended
by the manufacturers.
 |
RESULTS |
TM region of JSRV envelope is a determinant of cell transformation
in vitro.
The JSRV envelope precursor (as for all retroviruses) is
cleaved by cellular proteases into two proteins, surface (SU) and transmembrane (TM). SU is primarily responsible for the interaction with the cell surface receptor, while TM anchors the complex to the
virion envelope and is involved in later steps of viral entry (e.g.,
fusion). The exogenous JSRV envelope is highly related to its known
endogenous counterparts (3, 34). Between the exogenous and
the endogenous envelopes used in this study, there is 96% identity in
the SU region and 86% identity in the TM, but only approximately 50%
identity in VR3 (Fig. 2). We therefore reasoned that the VR3 might be important for viral transformation. To
this end we generated a series of chimeric envelopes between the
exogenous JSRV21 and the related endogenous
enJS56A1 in the context of the pCMV2JS21
GP envelope expression
plasmid (Fig. 1). These plasmids were tested in the standard NIH 3T3
cell focus formation assay.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 2.
Amino acid sequences of the TM region of JSRV and
enJSRV. (A) Alignment of the amino acid sequence of the TM region of
the exogenous JSRV21 and the endogenous enJS56A1 and
enJS5F16 clones. A dash (-) indicates lack of an amino acid. In bold
are the amino acids mutated in this study. The VR3 region is
underlined, and the putative PI-3K docking site is indicated by a
double arrow. (B) The putative PI-3K docking site is conserved among
various JSRV isolates (double arrow). GenBank accession numbers for the
exogenous sequences are AF105220 (JSRV21), AF357971 (JS7), NC001494
(JSRV-SA), Y18302 (809T), Y18303 (83R52), Y18304 (84R52), Y18305
(92K3), and Y16627 (ENTV).
|
|
As expected, pCMV3JS21
GP transformed NIH 3T3 cells (23.7 ± 12.7 foci [mean ± standard deviation]), while pEnvEn and
pEnvEn2 did not. The chimeric constructs pSUxTMen,
pSUxTMxVR3en, and pSUxTMxNruIen, containing, respectively, the
TM, the VR3, or only the carboxy-terminal 36 amino acids from the
endogenous loci, were not able to transform NIH 3T3 cells. This
indicated that sequences downstream from the NruI site in
the VR3 of JSRV are necessary for transformation, in agreement with our
initial hypothesis.
However, the reciprocal chimeras pSUenTMx and
pSUenTMenVR3x also did not transform NIH 3T3 cells.
These results could reflect an additional requirement for exogenous SU
to transform NIH 3T3 cells, or they could simply reflect differences in
expression and/or mRNA stability. To address this, we carried out
Northern blot analysis for env RNA from 293T cells
transiently transfected with pCMV2JS21, the exogenous
JSRV21 molecular clone driven by the CMV
immediate-early promoter (36), and with pen56A1
(34), a full-length endogenous molecular clone also driven
by the CMV immediate-early promoter (Fig.
3A). The results showed a great difference in expression of the spliced env mRNA, but there
was no difference in the levels of full-length unspliced viral RNAs. Thus, either the endogenous spliced env mRNA is relatively
unstable or its expression is repressed. This was supported by Northern blot analysis of 293T cells transfected with either pEnvEn,
pCMV2JS21
GP, or pSUxTMxNruIen. These constructs are all driven by
the same CMV promoter and have the same splice donor and splice
acceptor. However, spliced env mRNA from pEnvEn was not
expressed as efficiently as pCMV2JS21
GP or pSUxTMxNruIen, which
contain various amounts of exogenous JSRV env sequences
(Fig. 3B). Similarly, spliced env mRNA from the chimera
containing the endogenous env with the exogenous VR3 was
expressed at much lower levels than the full-length exogenous
counterpart; the latter is instead expressed as efficiently as the
wild-type pCMV2JS21
GP (Fig. 3C). A full description of the JSRV mRNA
splicing patterns and of the relative instability of the endogenous
mRNA transcripts will be discussed elsewhere (M. Palmarini, C. Murgia,
and H. Fan, submitted for publication). Briefly, all chimeras
that contained endogenous SU sequences showed substantially lower
levels of spliced env mRNA. Therefore, the failure of these
chimeras to transform could be simply attributed to low levels of
env mRNA, and they were not informative with regard to
env domains for transformation.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Northern blotting analysis of exogenous
JSRV21 full-length clone, endogenous en56A1 full-length
clone, and some chimeric Env constructs. 293T cells were transiently
transfected with the plasmids indicated below, and total RNA was
obtained 48 h after transfection and analyzed by Northern blotting
as described in Materials and Methods. (A) Comparison of full-length
exogenous pCMV2JS21 and pen56A1 clones. Three main transcripts are
visible in the pCMV2JS21 lane: a 7.5-kb band corresponding to the
canonical full-length mRNA, a 2.4-kb band corresponding to the spliced
mRNA encoding Env, and a 1.2-kb band corresponding to the prematurely
polyadenylated tr-env transcript (28). In
the pen56A1 lane, the full-length mRNA band has approximately the same
intensity as the equivalent band of the exogenous pCMV2JS21 clone, but
no spliced env mRNA is visible. (B and C) Western
blotting as above using various Env constructs. In panel B, note the
difference in expression between the endogenous pEnvEn (first lane) and
the exogenous pCMV3JS21 GP (last lane). The chimeric construct
pSUxTMxNruIen is expressed at a level comparable to that of the
exogenous pCMV3JS21 GP. pCMV2JS21 GP StuI
expresses the prematurely polyadenylated env transcript
and is not relevant for this study. (C) Difference in expression
between the chimera pSUxTMxVR3en and pSUenTMenVR3x. pSUenTMenVR3x is
not an informative construct because its expression is downregulated or
the resulting mRNA is unstable. pSUxTMxVR3en has a level of expression
comparable to that of the exogenous pCMV2JS21 GP.
|
|
Tyrosine residue in cytoplasmic tail of TM is necessary for
transformation.
The preceding experiments pointed to the VR3 of
JSRV as a main determinant of viral oncogenesis. The VR3 region
includes the cytoplasmic tail of the JSRV TM glycoprotein. Thus, the
cytoplasmic tail of the JSRV Env might mediate transformation by a cell
signaling mechanism. It was noteworthy that the VR3 region from all
exogenous strains of JSRV sequences contains a tyrosine residue (Y590
in JSRV21) (Fig. 2B), while the two endogenous
envelopes do not (Fig. 2A). Moreover, Y590 is in an amino acid sequence
that could potentially bind SH2 domain-containing proteins (see below).
To test if Y590 might be important for JSRV transformation, we mutated
Y590 in pCMV2JS21
GP to either phenylalanine (pCMV2JS21
GPY590F) or
aspartic acid (pCMV2JS21
GPY590D). Both
the Y590 mutants were completely unable to transform cells (Table
1). This indicated that Y590 is essential
for transformation.
There are five tyrosine residues in the TM protein of JSRV. To test if
the requirement for Y590 for transformation was specific, the other
tyrosines were also individually mutated to phenylalanines in the
context of pCMV2JS21
GP (Y419F, Y443F, Y468F, and Y478F). All of
these mutants resulted in transformation (Table 1). Thus, mutation of
only Y590 abolished transformation, indicating that the requirement for
Y590 for transformation was quite specific.
Docking site for PI-3K but not Grb-2 is essential for
transformation.
The amino acid sequence surrounding the Y590 in
the JSRV TM cytoplasmic tail is YRNM. This sequence contains potential
binding sites for two classes of SH2 domain-containing proteins: YXXM for the regulatory alpha subunit of PI-3K (p85) and YXN for the growth
factor receptor binding protein 2 (Grb-2) (9, 43). Both of
these proteins are at the beginning of important signal transduction
cascades. Mutation of the methionine at position 593 (M593T) completely
abolished transformation, while mutation of the asparagine at residue
592 (N592T) did not. These results indicated that binding of Grb-2 and
signaling through the Ras/Raf/mitogen-activated protein kinase (MAPK)
pathway was not essential for JSRV transformation, although we cannot
rule out that the Ras/MAPK pathway could still be activated in a
different manner at some other level. In contrast, the results also
supported the possibility that docking of PI-3K to the cytoplasmic tail
of JSRV TM protein is essential for transformation.
Mutations of Y590 do not abolish ability of JSRV Env to bind
receptor and mediate viral entry.
We next considered whether the
mutations abolishing the transforming phenotype of the JSRV envelope
were merely causing conformational changes in the JSRV envelope protein
that might prevent the correct expression and/or interaction with the
cellular receptor. To address this, we tested the capacity of the
critical Y590 envelope mutants to mediate viral entry. Entry assays
were performed using MLV-based vectors expressing the luciferase genes
pseudotyped with various envelope constructs. The viral pseudotypes
were then used to infect 3T3 cells stably expressing the JSRV cellular
receptor (M. Palmarini and H. Fan, unpublished results), and luciferase
activity was measured 3 days postinfection (Fig.
4). In the same experiment we used the
wild-type pCMV2JS21
GP and plasmids pSUxTMxNruIen, pEnvEn, and
pSUxTMen.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 4.
Entry assays employing MLV-luciferase vectors
pseudotyping some of the chimeric and mutant constructs described in
this study. Values are expressed as relative light units (RLU);
threefold dilutions were used in this experiment. PCMV3JS21 GP,
pCMV3JS21 GPY590D, and
pSUxTMxNruIen all gave comparable values. pCMV3JS21Y590F gives
values approximately 50% of those of the above plasmids but well above
the background given by pSUenTMx and pEnvEn, which, as expected,
represent the baseline close to zero (considering that these constructs
are not efficiently expressed, as established by Northern blotting).
The values are the averages of duplicate experiments for each dilution.
The experiments were repeated once with a different DNA plasmid
preparation and gave essentially the same results (not shown).
|
|
No significant differences were observed in the luciferase values
between the wild-type pCMV2JS21
GP,
pCMV2JS21
GPY590D, and pSUxTMxNruIen.
pCMV2JS21
GPY590F showed decreased luciferase values with respect to
the wild-type pCMV2JS21
GP. pSUenTMex and pEnvEn showed no luciferase
activity; this was presumably due to the inability of these constructs
to be expressed efficiently. However, it is also possible that the
endogenous envelope does not bind the same cellular receptor as the
exogenous counterpart. In any event, these experiments show that the
putative docking site for PI-3K in the JSRV VR3 region is absolutely
necessary for transformation but not for the viral envelope interaction
with the cellular receptor and subsequent entry into the cell. This
also indicates that the Y590F or Y590D mutations did not have global
effects on envelope conformation.
We also tested the functionality of the Y590 envelope mutants in viral
replication. The Y590F mutation was cloned into the pCMV2JS21 plasmid,
which contains a complete provirus under control of the CMV
immediate-early promoter. We generated Y590F mutant virus by
transfection of 293T cells, as described previously (36). The resulting virus was then used to infect sheep choroid plexus (CP)
cells in vitro, as described previously (37). PCR tests of
the infected CP cells indicated that the Y590F mutant virus was capable
of replication (not shown). However, due to the nature of the PCR-based
assay (the only one available for assaying JSRV infectivity in vitro),
quantitative assessment of the relative infectivity of the mutant virus
was not possible.
Phosphorylated Akt is present in JSRV-transformed but not parental
NIH 3T3 cells.
The results in Table
2 strongly suggested that JSRV Env
protein transforms cells by docking PI-3K to the cytoplasmic tail of
TM. The Akt protein kinase is an important intermediate in the PI-3K
signaling pathway. PI-3K activates Akt by phosphorylation of serine 473 and threonine 308 via the intermediate PDK-1 (14). If JSRV transforms cells via the PI-3K pathway, transformed cells would
be expected to show activation of intermediates in this pathway.
Therefore we tested two JSRV-transformed cell lines (MP1 and MP2) for
phosphorylation of Akt by Western blotting with Akt antibodies specific
for S473 and T308 phosphorylation (Fig.
5). Phosphorylated Akt was detected in
serum-starved MP1 cells but not in the parental NIH 3T3 cells. Akt in
MP1 cells is in its fully active form, because we could detect both
phosphorylated serine 473 and phosphorylated threonine 308 (Fig. 5).
Similar results were shown in MP2 cells (not shown). These results
strongly support the hypothesis that the cytoplasmic tail of the JSRV
envelope mediates transformation via the PI-3K/Akt cell signaling
pathway.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Transformation assays with JSRV Env constructs carrying
mutations in the SH-2 site of the cytoplasmic tail
|
|

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 5.
Activation of Akt in MP1 cells. Cell lysates of
serum-starved MP1 and NIH 3T3 cells were analyzed by SDS-PAGE-Western
blotting as described in Materials and Methods. Akt phosphorylated both
in serine and in threonine is visible in MP1 cells but not in the
parental NIH 3T3 cells. The same lysates were analyzed by using an
antiserum to Akt as a loading control.
|
|
 |
DISCUSSION |
Our previous work has established that the JSRV envelope has the
capacity to transform NIH 3T3 cells in classical transformation assays.
In this study we have demonstrated that (i) the cytoplasmic tail of the
transmembrane region of the JSRV envelope is critical for mediating
virus-induced transformation of NIH 3T3 cells and (ii) the PI-3K/Akt
pathway is activated in JSRV-transformed NIH 3T3 cells. These
conclusions have been drawn by abolishing the transforming phenotype of
JSRV through single point mutations (Y590F or Y590D and M593T) in a
putative PI-3K docking site (Y-X-X-M) of the TM cytoplasmic tail. In
some cells, PI-3K initiates a cell signaling pathway that appears to
inhibit apoptosis and be required for a number of mitogens during the
G1-to-S-phase transition of the cell cycle
(43). Akt (also known as protein kinase B) is a central
effector of the PI-3K pathway. PI-3K activates Akt by phosphorylation
of serine 473 and threonine 308 via the intermediate PDK-1
(14). We detected phosphorylation of Akt both in serine and in threonine in JSRV-transformed cells but not in the parental NIH
3T3 cells (Fig. 5).
These results suggest that a central event in JSRV-induced
transformation of NIH 3T3 cells is the activation of the PI-3K/Akt pathway resulting from the expression of the JSRV envelope and the
phosphorylation of Y590 in the cytoplasmic tail of the transmembrane region (Fig. 6). This would furnish a
novel mechanism of transformation for retroviruses. However, the
PI-3K/Akt pathway has been implicated in retrovirus-induced cell
transformation in other systems. Both PI-3K and Akt have been described
as retrovirus-transduced oncogenes. The catalytic subunit of PI-3K has
been transduced by avian sarcoma virus 16 (11), while Akt
has been transduced by an ecotropic MLV (7, 49). In
addition, the PI-3K/Akt pathway has recently been found to be involved
in the induction of erythropoietin independence of erythroid cells
following infection with Friend spleen focus-forming virus
(29). Thus, it is plausible that the PI-3K/Akt pathway could be the cause of the transformation events that occur in JSRV-transformed cells. Moreover, PI-3K/Akt cell signaling has been
shown to be activated in a number of solid human tumors, including lung
cancers (24, 28, 38, 48).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
Model of JSRV-induced transformation of NIH 3T3 cells.
The cytoplasmic tail of JSRV mediates transformation of NIH 3T3 cells
possibly via activation of the PI-3K/Akt pathway. Y590 in the
cytoplasmic tail of the JSRV Env needs to be phosphorylated in order to
activate the PI-3K pathway. It is not yet clear which interactions at
the membrane and/or at the cytoplasmic level are necessary in order for
transformation to occur.
|
|
Akt promotes cell survival by inhibiting apoptosis by phosphorylating
several targets, primarily the proapoptotic BCL-2 family member
BAD (10), forkhead transcription factors
(8), and the cell death pathway enzyme caspase-9
(44). In addition, Akt activates the ribosomal S6 kinase
(p70S6K) (13) via FRAP (also
known as mTOR) phosphorylation. Activation of
p70S6K regulates a wide variety of cellular
processes involved in the mitogenic response (12, 15, 18).
One impediment to this research is the fact that no effective
antibodies specific for JSRV envelope protein have been developed yet.
The development of such reagents will be necessary in order to further
dissect the cell signaling activated in JSRV-transformed NIH 3T3 cells
and to establish if indeed the JSRV Env is phosphorylated. A first
priority will be to test if the tyrosine at 590 is in fact
phosphorylated in transformed cells, a prerequisite for docking of
PI-3K. Other important issues to address in the future are to identify
the particular proteins that interact with the JSRV Env (e.g., PI-3K)
and to determine if interaction with the JSRV cellular receptor Hyal-2
is also necessary for JSRV-induced transformation. The murine Hyal-2
does not mediate efficient JSRV entry (41); however, this
does not necessarily imply that there is not an interaction between
JSRV Env and murine Hyal-2 that could be necessary for transformation.
Abundant JSRV Env expression appears to be necessary for transformation
of NIH 3T3 cells. Indeed, if the JSRV Env is driven by the JSRV long
terminal repeat (LTR), which is a relatively weak promoter in NIH 3T3
cells, transformation is inefficient (27). An analogous
situation might pertain to in vivo infection. In OPC-affected animals,
JSRV infects a wide variety of lymphoid tissues and cells (20,
22, 35), but viral antigen is consistently easily detected only
in differentiated lung epithelial cells (32). This is
because the JSRV LTR is specifically active in the target cells for
viral transformation (31). Thus, activation of the
PI-3K/Akt pathway will preferentially occur in lung epithelial cells,
where the JSRV LTR is efficiently expressed.
Recent data suggest that in type II pneumocytes, surfactant protein A
(SP-A) regulates the production of pulmonary surfactant secretion via
activation of the PI-3K/Akt pathway (53). In turn, SP-A
increases transcription of another surfactant protein, SP-B, by
enhancing the activity of lung-specific transcription factors like
hepatocyte nuclear factor HNF-3 (50). Thus, it
might be envisaged that JSRV expression in transformed type II
pneumocytes involves an autocrine loop in which lung-specific
transcription factors activate the JSRV LTR; the resulting Env
expression leads to constitutive activation of the PI-3K/Akt pathway,
which in turn enhances expression of lung-specific transcription
factors. Activation of the PI-3K/Akt pathway might be only one of
several hits required for transformation in vivo, particularly in
naturally occurring OPC, where the incubation period can be several
months or even years. There are other examples of retroviral
oncogenesis that would support this view. For instance, Abelson MLV
induces cell transformation in vitro by the expression of a Gag-Abl
fusion protein (19). In vivo, however, it has been shown
that insertional activation by a Moloney MLV helper virus is also
required to induce leukemia (39, 40). Experimental
inoculation of newborn lambs with replication-competent JSRV Y590/M593
mutants will directly address whether activation of the PI-3K/Akt
pathway is also essential for transformation in vivo. Furthermore,
studies on OPC tumor-derived cell lines might help to address this issue.
Given the unique tropism for the differentiated epithelial cells of the
lungs, JSRV is also being considered as a potential vector for gene
transfer in lung cells. However, the ability of JSRV envelope protein
to induce transformation is clearly a point of concern for development
of JSRV-based vectors. This study provides a way to uncouple the
unwanted transforming properties of the JSRV envelope from the desired
ability to mediate viral entry.
M.P. was a recipient of an American Cancer Society Ray and Estelle
Spehar Fellowship. This work was supported by NIH grant RO1CA82564 to
H.F. and by the University of Georgia (to M.P.). Support from the UCI
Cancer Research Institute and the DNA sequencing core of the Chao
Family Comprehensive Cancer Center is acknowledged.
| 1.
|
Auerbach, O., and L. Garfinkel.
1991.
The changing pattern of lung carcinoma.
Cancer
68:1973-1977[CrossRef][Medline].
|
| 2.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl (ed.).
2000.
Current protocols in molecular biology.
John Wiley and Son, New York, N.Y.
|
| 3.
|
Bai, J.,
J. V. Bishop,
J. O. Carlson, and J. C. DeMartini.
1999.
Sequence comparison of JSRV with endogenous proviruses: envelope genotypes and a novel ORF with similarity to a G-protein-coupled receptor.
Virology
258:333-343[CrossRef][Medline].
|
| 4.
|
Bai, J.,
R. Y. Zhu,
K. Stedman,
C. Cousens,
J. Carlson,
J. M. Sharp, and J. C. DeMartini.
1996.
Unique long terminal repeat U3 sequences distinguish exogenous Jaagsiekte sheep retroviruses associated with ovine pulmonary carcinoma from endogenous loci in the sheep genome.
J. Virol.
70:3159-3168[Abstract].
|
| 5.
|
Barkley, J. E., and M. R. Green.
1996.
Bronchioloalveolar carcinoma.
J. Clin. Oncol.
14:2377-2386[Abstract].
|
| 6.
|
Barsky, S. H.,
R. Cameron,
K. E. Osann,
D. Tomita, and E. C. Holmes.
1994.
Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features.
Cancer
73:1163-1170[CrossRef][Medline].
|
| 7.
|
Bellacosa, A.,
J. R. Testa,
S. P. Staal, and P. N. Tsichlis.
1991.
A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.
Science
254:274-277[Abstract/Free Full Text].
|
| 8.
|
Brunet, A.,
A. Bonni,
M. J. Zigmond,
M. Z. Lin,
P. Juo,
L. S. Hu,
M. J. Anderson,
K. C. Arden,
J. Blenis, and M. E. Greenberg.
1999.
Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor.
Cell
96:857-868[CrossRef][Medline].
|
| 9.
|
Buday, L., and J. Downward.
1993.
Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor.
Cell
73:611-620[CrossRef][Medline].
|
| 10.
|
Cardone, M. H.,
N. Roy,
H. R. Stennicke,
G. S. Salvesen,
T. F. Franke,
E. Stanbridge,
S. Frisch, and J. C. Reed.
1998.
Regulation of cell death protease caspase-9 by phosphorylation.
Science
282:1318-1321[Abstract/Free Full Text].
|
| 11.
|
Chang, H. W.,
M. Aoki,
D. Fruman,
K. R. Auger,
A. Bellacosa,
P. N. Tsichlis,
L. C. Cantley,
T. M. Roberts, and P. K. Vogt.
1997.
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.
Science
276:1848-1850[Abstract/Free Full Text].
|
| 12.
|
Chou, M. M., and J. Blenis.
1995.
The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling.
Curr. Opin. Cell Biol.
7:806-814[CrossRef][Medline].
|
| 13.
|
Chung, J.,
T. C. Grammer,
K. P. Lemon,
A. Kazlauskas, and J. Blenis.
1994.
PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase.
Nature
370:71-75[CrossRef][Medline].
|
| 14.
|
Datta, S. R.,
A. Brunet, and M. E. Greenberg.
1999.
Cellular survival: a play in three Akts.
Genes Dev.
13:2905-2927[Free Full Text].
|
| 15.
|
de Groot, R. P.,
L. M. Ballou, and P. Sassone-Corsi.
1994.
Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression.
Cell
79:81-91[CrossRef][Medline].
|
| 16.
|
DeMartini, J. C.,
J. V. Bishop,
T. E. Allen,
F. A. Jassim,
J. M. Sharp,
M. de Las Heras,
D. R. Voelker, and J. O. Carlson.
2001.
Jaagsiekte sheep retrovirus proviral clone JSRV(JS7), derived from the JS7 lung tumor cell line, induces ovine pulmonary carcinoma and is integrated into the surfactant protein A gene.
J. Virol.
75:4239-4246[Abstract/Free Full Text].
|
| 17.
|
DeMartini, J. C., and D. F. York.
1997.
Retrovirus-associated neoplasms of the respiratory system of sheep and goats. Ovine pulmonary carcinoma and enzootic nasal tumor.
Vet. Clin. N. Am. Food Anim. Pract.
13:55-70[Medline].
|
| 18.
|
Ferrari, S., and G. Thomas.
1994.
S6 phosphorylation and the p70s6k/p85s6k.
Crit. Rev. Biochem. Mol. Biol.
29:385-413[Medline].
|
| 19.
|
Goff, S. P.,
O. N. Witte,
E. Gilboa,
N. Rosenberg, and D. Baltimore.
1981.
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells.
J. Virol.
38:460-468[Abstract/Free Full Text].
|
| 20.
|
Gonzalez, L.,
M. Garcia-Goti,
C. Cousens,
P. Dewar,
N. Cortabarria,
A. B. Extramiana,
A. Ortin,
M. De Las Heras, and J. M. Sharp.
2001.
Jaagsiekte sheep retrovirus can be detected in the peripheral blood during the preclinical period of sheep pulmonary adenomatosis.
J. Gen. Virol.
82:1355-1358[Abstract/Free Full Text].
|
| 21.
|
Greco, R. J.,
R. M. Steiner,
S. Goldman,
H. Cotler,
A. Patchefsky, and H. E. Cohn.
1986.
Bronchoalveolar cell carcinoma of the lung.
Ann. Thorac. Surg.
41:652-656[Abstract].
|
| 22.
|
Holland, M. J.,
M. Palmarini,
M. Garcia-Goti,
L. Gonzalez,
I. Mckendrick,
M. De las Heras, and J. M. Sharp.
1999.
Jaagsiekte retrovirus is widely distributed in both T and B lymphocytes and mononuclear phagocytes of sheep with naturally and experimentally acquired pulmonary adenomatosis.
J. Virol.
73:4004-4008[Abstract/Free Full Text].
|
| 23.
|
Ives, J. C.,
P. A. Buffler, and S. D. Greenberg.
1983.
Environmental associations and histopathologic patterns of carcinoma of the lung: the challenge and dilemma in epidemiologic studies.
Am. Rev. Respir. Dis.
128:195-209[Medline].
|
| 24.
|
Kobayashi, M.,
S. Nagata,
T. Iwasaki,
K. Yanagihara,
I. Saitoh,
Y. Karouji,
S. Ihara, and Y. Fukui.
1999.
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Proc. Natl. Acad. Sci. USA
96:4874-4879[Abstract/Free Full Text].
|
| 25.
|
Lepperdinger, G.,
B. Strobl, and G. Kreil.
1998.
HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity.
J. Biol. Chem.
273:22466-22470[Abstract/Free Full Text].
|
| 26.
|
Lerman, M. I., and J. D. Minna.
2000.
The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Cancer Res.
60:6116-6133[Abstract/Free Full Text].
|
| 27.
|
Maeda, N.,
M. Palmarini,
C. Murgia, and H. Fan.
2001.
Direct transformation of rodent fibroblasts by Jaagsiekte sheep retrovirus DNA.
Proc. Natl. Acad. Sci. USA
98:4449-4454[Abstract/Free Full Text].
|
| 28.
|
Moore, S. M.,
R. C. Rintoul,
T. R. Walker,
E. R. Chilvers,
C. Haslett, and T. Sethi.
1998.
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.
Cancer Res.
58:5239-5247[Abstract/Free Full Text].
|
| 29.
|
Nishigaki, K.,
C. Hanson,
T. Ohashi,
D. Thompson,
K. Muszynski, and S. Ruscetti.
2000.
Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.
J. Virol.
74:3037-3045[Abstract/Free Full Text].
|
| 30.
|
Palmarini, M.,
C. Cousens,
R. G. Dalziel,
J. Bai,
K. Stedman,
J. C. DeMartini, and J. M. Sharp.
1996.
The exogenous form of Jaagsiekte retrovirus is specifically associated with a contagious lung cancer of sheep.
J. Virol.
70:1618-1623[Abstract].
|
| 31.
|
Palmarini, M.,
S. Datta,
R. Omid,
C. Murgia, and H. Fan.
2000.
The long terminal repeats of Jaagsiekte sheep retrovirus are preferentially active in type II pneumocytes.
J. Virol.
74:5776-5787[Abstract/Free Full Text].
|
| 32.
|
Palmarini, M.,
P. Dewar,
M. De las Heras,
N. F. Inglis,
R. G. Dalziel, and J. M. Sharp.
1995.
Epithelial tumour cells in the lungs of sheep with pulmonary adenomatosis are major sites of replication for Jaagsiekte retrovirus.
J. Gen. Virol.
76:2731-2737[Abstract/Free Full Text].
|
| 33.
|
Palmarini, M.,
H. Fan, and J. M. Sharp.
1997.
Sheep pulmonary adenomatosis: a unique model of retrovirus-associated lung cancer.
Trends Microbiol.
5:478-483[CrossRef][Medline].
|
| 34.
|
Palmarini, M.,
C. Hallwirth,
D. York,
C. Murgia,
T. de Oliveira,
T. Spencer, and H. Fan.
2000.
Molecular cloning and functional analysis of three type D endogenous retroviruses of sheep reveals a different cell tropism from that of the highly related exogenous Jaagsiekte sheep retrovirus.
J. Virol.
74:8065-8076[Abstract/Free Full Text].
|
| 35.
|
Palmarini, M.,
M. J. Holland,
C. Cousens,
R. G. Dalziel, and J. M. Sharp.
1996.
Jaagsiekte retrovirus establishes a disseminated infection of the lymphoid tissues of sheep affected by pulmonary adenomatosis.
J. Gen. Virol.
77:2991-2998[Abstract/Free Full Text].
|
| 36.
|
Palmarini, M.,
J. M. Sharp,
M. De las Heras, and H. Fan.
1999.
Jaagsiekte sheep retrovirus is necessary and sufficient to induce a contagious lung cancer in sheep.
J. Virol.
73:6964-6972[Abstract/Free Full Text].
|
| 37.
|
Palmarini, M.,
J. M. Sharp,
C. Lee, and H. Fan.
1999.
In vitro infection of ovine cell lines by Jaagsiekte sheep retrovirus.
J. Virol.
73:10070-10078[Abstract/Free Full Text].
|
| 38.
|
Phillips, W. A.,
F. St. Clair,
A. D. Munday,
R. J. Thomas, and C. A. Mitchell.
1998.
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Cancer
83:41-47[CrossRef][Medline].
|
| 39.
|
Poirier, Y., and P. Jolicoeur.
1989.
Distinct helper virus requirements for Abelson murine leukemia virus-induced pre-B- and T-cell lymphomas.
J. Virol.
63:2088-2098[Abstract/Free Full Text].
|
| 40.
|
Poirier, Y.,
C. Kozak, and P. Jolicoeur.
1988.
Identification of a common helper provirus integration site in Abelson murine leukemia virus-induced lymphoma DNA.
J. Virol.
62:3985-3992[Abstract/Free Full Text].
|
| 41.
|
Rai, S. K.,
J. C. DeMartini, and A. D. Miller.
2000.
Retrovirus vectors bearing Jaagsiekte sheep retrovirus Env transduce human cells by using a new receptor localized to chromosome 3p21.3.
J. Virol.
74:4698-4704[Abstract/Free Full Text].
|
| 42.
|
Rai, S. K.,
F. M. Duh,
V. Vigdorovich,
A. Danilkovitch-Miagkova,
M. I. Lerman, and A. D. Miller.
2001.
Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for Jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation.
Proc. Natl. Acad. Sci. USA
98:4443-4448[Abstract/Free Full Text].
|
| 43.
|
Roche, S.,
M. Koegl, and S. A. Courtneidge.
1994.
The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors.
Proc. Natl. Acad. Sci. USA
91:9185-9189[Abstract/Free Full Text].
|
| 44.
|
Rommel, C.,
B. A. Clarke,
S. Zimmermann,
L. Nunez,
R. Rossman,
K. Reid,
K. Moelling,
G. D. Yancopoulos, and D. J. Glass.
1999.
Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.
Science
286:1738-1741[Abstract/Free Full Text].
|
| 45.
|
Rosenberg, N.
2001.
New transformation tricks from a barnyard retrovirus: implications for human lung cancer.
Proc. Natl. Acad. Sci. USA
98:4285-4287[Free Full Text].
|
| 46.
|
Rosenberg, N., and P. Jolicoeur.
1997.
Retroviral pathogenesis, p. 475-585.
In
J. M. Coffin, S. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 47.
|
Sharp, J. M.,
K. W. Angus,
E. W. Gray, and F. M. Scott.
1983.
Rapid transmission of sheep pulmonary adenomatosis (Jaagsiekte) in young lambs.
Arch. Virol.
78:89-95[CrossRef][Medline].
|
| 48.
|
Shayesteh, L.,
Y. Lu,
W. L. Kuo,
R. Baldocchi,
T. Godfrey,
C. Collins,
D. Pinkel,
B. Powell,
G. B. Mills, and J. W. Gray.
1999.
PIK3CA is implicated as an oncogene in ovarian cancer.
Nat. Genet.
21:99-102[CrossRef][Medline].
|
| 49.
|
Staal, S. P.,
J. W. Hartley, and W. P. Rowe.
1977.
Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma.
Proc. Natl. Acad. Sci. USA
74:3065-3067[Abstract/Free Full Text].
|
| 50.
|
Strayer, D. S., and L. Korutla.
2000.
Activation of surfactant protein-B transcription: signaling through the SP-A receptor utilizing the PI3 kinase pathway.
J. Cell Physiol.
184:229-238[CrossRef][Medline].
|
| 51.
|
Valaitis, J.,
S. Warren, and D. Gamble.
1981.
Increasing incidence of adenocarcinoma of the lung.
Cancer
47:1042-1046[CrossRef][Medline].
|
| 52.
|
Verwoerd, D. W.,
E. M. De Villiers, and R. C. Tustin.
1980.
Aetiology of Jaagsiekte: experimental transmission to lambs by means of cultured cells and cell homogenates.
Onderstepoort J. Vet. Res.
47:13-18[Medline].
|
| 53.
|
White, M. K., and D. S. Strayer.
2000.
Surfactant protein A regulates pulmonary surfactant secretion via activation of phosphatidylinositol 3-kinase in type II alveolar cells.
Exp. Cell Res.
255:67-76[CrossRef][Medline].
|